Willingness to Take Long-acting Injectable Pre-exposure Prophylaxis Among Men Who Have Sex with Men Who Participated in the CROPrEP Study: a Cross-sectional Online Study

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2023 Dec 13

PMID 38093204

Authors

Yingjie Liu

Zhenxing Chu

Hongyi Wang

Xiaojie Huang

Yaokai Chen

Hui Wang

Dehua Zou

Yongjun Jiang

Wenqing Geng

Qinghai Hu

Baosen Zhou

Hong Shang

Affiliations

Soon will be listed here.

Abstract

Introduction: Evidence on the willingness of men who have sex with men (MSM) with oral pre-exposure prophylaxis (PrEP) experience, especially those with suboptimal adherence, to take long-acting injectable PrEP (LAI-PrEP) is critical to guide future LAI-PrEP implementation.

Objective: The objective was to assess the willingness of MSM with oral PrEP experience to take LAI-PrEP.

Methods: MSM who participated in the China Real-world Study of Oral PrEP (CROPrEP) were enrolled in this study. Information on the willingness of MSM to take LAI-PrEP and potential correlates was collected using a structured online questionnaire. The main outcomes were the willingness of MSM to take LAI-PrEP and its association with HIV-related behaviours, sexually transmitted infections, and oral PrEP history. Logistic regression was used to identify correlates of the willingness of MSM to take LAI-PrEP.

Results: A total of 612 former CROPrEP participants (FCPs) were included in this study. There were 315 (51.5%) daily oral PrEP (D-PrEP) users and 297 (48.5%) event-driven oral PrEP (ED-PrEP) users at the last follow-up. Most FCPs (77.8%) were willing to take free LAI-PrEP. FCPs with no less than two sexual male partners (aOR = 1.54, [95% CI: 1.04, 2.29], P = 0.031), those with male partners with unknown HIV statuses (aOR = 2.04, [95% CI: 1.31, 3.18], P = 0.002), those with recreational drug use (aOR = 1.58, [95% CI: 1.05, 2.40], P = 0.030), and those with HSV-2 positivity (aOR = 2.15, [95% CI: 1.30, 3.57], P = 0.003) were more willing to take LAI-PrEP, while ED-PrEP users (aOR = 0.66, [95% CI: 0.45, 0.98], P = 0.037) and FCPs with suboptimal oral PrEP adherence (aOR = 0.58, [95% CI: 0.36, 0.94], P = 0.026) were less willing to take LAI-PrEP.

Conclusion: LAI-PrEP has good prospects for expanding PrEP coverage. However, FCPs with suboptimal oral PrEP adherence are less likely to take LAI-PrEP. Further intervention and implementation efforts are needed to improve the willingness of MSM to use LAI-PrEP, and sexual health should be considered during the discussion about PrEP initiation.

Citing Articles

Willingness to Use Long-Acting Injectable Pre-Exposure Prophylaxis among Adolescent Girls and Young Women in Kampala, Uganda.

Lunkuse J, Lwanga C, Wamono F, Muturi-Kioi V, Price M, Mayanja Y AIDS Behav. 2025; .

PMID: 39883369 DOI: 10.1007/s10461-025-04616-y.

References

Chan C, Vaccher S, Fraser D, Grulich A, Holt M, Zablotska-Manos I . Preferences for Current and Future PrEP Modalities Among PrEP-Experienced Gay and Bisexual Men in Australia. AIDS Behav. 2021; 26(1):88-95. DOI: 10.1007/s10461-021-03344-3. View

Huang W, Wu D, Ong J, Smith M, Pan S, Yang F . Prepared for PrEP: preferences for HIV pre-exposure prophylaxis among Chinese men who have sex with men in an online national survey. BMC Infect Dis. 2019; 19(1):1057. PMC: 6916236. DOI: 10.1186/s12879-019-4692-x. View

Ching S, Wong L, Said M, Lim S . Meta-synthesis of Qualitative Research of Pre-exposure Prophylaxis (PrEP) Adherence Among Men Who Have Sex With Men (MSM). AIDS Educ Prev. 2020; 32(5):416-431. DOI: 10.1521/aeap.2020.32.5.416. View

. [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)]. Zhonghua Nei Ke Za Zhi. 2021; 60(12):1106-1128. DOI: 10.3760/cma.j.cn112138-20211006-00676. View

Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J . Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China. AIDS Behav. 2017; 22(4):1217-1227. PMC: 5767147. DOI: 10.1007/s10461-017-1845-z. View

Ouedraogo H, Zida S, Sagna T, Zoure A, Compaore R, Soubeiga S . Herpes simplex virus type 2 (HSV-2) and its association with HIV, HCV, HBV, HTLV-1&2 and syphilis among men who have sex with men in Burkina Faso. Indian J Med Microbiol. 2022; 42:59-64. DOI: 10.1016/j.ijmmb.2022.09.007. View

Levy M, Agopian A, Magnus M, Rawls A, Opoku J, Kharfen M . Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?. J Acquir Immune Defic Syndr. 2020; 86(3):e80-e82. PMC: 7975625. DOI: 10.1097/QAI.0000000000002557. View

Zhang J, Li C, Xu J, Hu Z, Rutstein S, Tucker J . Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022; 9(4):e254-e268. PMC: 9124596. DOI: 10.1016/S2352-3018(22)00030-3. View

Molina J, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G . Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022; 9(8):e554-e562. DOI: 10.1016/S2352-3018(22)00133-3. View

10.

Zhang H, Wang M, Zhang Y, Tan S, Huang H, Zhu J . Usability of dual HIV/syphilis self-testing among men who have sex with men in China: study protocol for a three-arm randomised controlled trial. BMJ Open. 2022; 12(10):e059034. PMC: 9558798. DOI: 10.1136/bmjopen-2021-059034. View

11.

Sued O, Nardi N, Spadaccini L . Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS. 2022; 17(3):145-161. DOI: 10.1097/COH.0000000000000734. View

12.

Huang X, Hou J, Song A, Liu X, Yang X, Xu J . Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018; 9:799. PMC: 6131617. DOI: 10.3389/fphar.2018.00799. View

13.

Wang H, Wang Z, Huang X, Chen Y, Wang H, Cui S . Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial. JAMA Netw Open. 2022; 5(2):e2148782. PMC: 8851305. DOI: 10.1001/jamanetworkopen.2021.48782. View

14.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

15.

Ogunbajo A, Tsai A, Kanki P, Mayer K . Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa. AIDS Behav. 2022; 26(7):2363-2375. PMC: 10921337. DOI: 10.1007/s10461-022-03575-y. View

16.

Agrahari V, Anderson S, Peet M, Wong A, Singh O, Doncel G . Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. Expert Opin Drug Deliv. 2022; 19(10):1365-1380. PMC: 9639748. DOI: 10.1080/17425247.2022.2135699. View

17.

Garrison L, Haberer J . Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S. Am J Prev Med. 2021; 61(5 Suppl 1):S73-S86. DOI: 10.1016/j.amepre.2021.04.036. View

18.

Ellison J, Berg J, Montgomery M, Tao J, Pashankar R, Mimiaga M . Next-Generation HIV Pre-Exposure Prophylaxis Preferences Among Men Who Have Sex with Men Taking Daily Oral Pre-Exposure Prophylaxis. AIDS Patient Care STDS. 2019; 33(11):482-491. PMC: 6839421. DOI: 10.1089/apc.2019.0093. View

19.

Anderson P, Glidden D, Liu A, Buchbinder S, Lama J, Guanira J . Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra125. PMC: 3721979. DOI: 10.1126/scitranslmed.3004006. View

20.

Chen W, Ding Y, Chen J, Zhao P, Wang Z, Meng X . Awareness of and Preferences for Preexposure Prophylaxis (PrEP) among MSM at High Risk of HIV Infection in Southern China: Findings from the T2T Study. Biomed Res Int. 2021; 2021:6682932. PMC: 8035020. DOI: 10.1155/2021/6682932. View